Adaptimmune Therapeutics PLC
ADAPY Healthcare Biotechnology
Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024. In the quarter to June 2025, revenue fell 89.3%, EPS fell 140.7% and free cash flow fell 174.7%, each against the same quarter a year earlier.
Follow ADAPY
Adaptimmune Therapeutics PLC (ADAPY) EV/Sales
As of 16 October 2026, Adaptimmune Therapeutics PLC (ADAPY) trades at a EV/Sales of 0.1×. Over the past ten years it has ranged from −12.5× (March 2022) to 700× (June 2020); the current reading is higher than 23% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.1× | (40.89%) |
| FY2024 | 0.2× | (51.58%) |
| FY2023 | 0.4× | (87.07%) |
| FY2022 | 3.1× | (91.91%) |
| FY2021 | 38.7× | (63.60%) |
| FY2020 | 106× | 365.44% |
| FY2019 | 22.8× | 282.86% |
| FY2018 | 6.0× | (45.78%) |
| FY2017 | 11.0× | 41.75% |
| FY2016 | 7.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2025 | 1.0× | 908.23% |
| Mar 2025 | 0.1× | (51.00%) |
| Dec 2024 | 0.2× | (67.88%) |
| Sep 2024 | 0.6× | 9.85% |
| 36 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LPCN Lipocine Inc. compare | −5.2× |
| ADAPY Adaptimmune Therapeutics PLC | 0.1× |
| RVLP RVL Pharmaceuticals PLC compare | 1.0× |
| CLVSQ Clovis Oncology, Inc. compare | 3.1× |
| CNSY Cerenome, Inc. compare | 3.3× |
| DARE Dare Bioscience, Inc. compare | 4.7× |
| TVRD Tvardi Therapeutics, Inc. compare | 4.8× |
| BCDA BioCardia, Inc. compare | 30.2× |
| GTBP GT Biopharma, Inc. compare | 543× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)